ReWalk Robotics Ltd., a medical device company, designs, develops, and commercializes robotic exoskeletons for individuals with mobility impairments or other medical conditions.
+ 1 more risk
Adequate balance sheet with limited growth.
Share Price & News
How has ReWalk Robotics's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: 2RW's share price has been volatile over the past 3 months.
7 Day Return
DE Medical Equipment
1 Year Return
DE Medical Equipment
Return vs Industry: 2RW underperformed the German Medical Equipment industry which returned 38.3% over the past year.
Return vs Market: 2RW underperformed the German Market which returned -0.1% over the past year.
Price Volatility Vs. Market
How volatile is ReWalk Robotics's share price compared to the market and industry in the last 5 years?
Simply Wall St News
No news available
Is ReWalk Robotics undervalued compared to its fair value and its price relative to the market?
Price to Book (PB) ratio
Share Price vs. Fair Value
Below Fair Value: Insufficient data to calculate 2RW's fair value to establish if it is undervalued.
Significantly Below Fair Value: Insufficient data to calculate 2RW's fair value to establish if it is undervalued.
Price To Earnings Ratio
PE vs Industry: 2RW is unprofitable, so we can't compare its PE Ratio to the Medical Equipment industry average.
PE vs Market: 2RW is unprofitable, so we can't compare its PE Ratio to the German market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate 2RW's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: 2RW is good value based on its PB Ratio (0.9x) compared to the DE Medical Equipment industry average (4.9x).
How is ReWalk Robotics forecast to perform in the next 1 to 3 years based on estimates from 1 analyst?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: 2RW is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: 2RW is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: 2RW is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: 2RW's revenue (32.9% per year) is forecast to grow faster than the German market (5.7% per year).
High Growth Revenue: 2RW's revenue (32.9% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if 2RW's Return on Equity is forecast to be high in 3 years time
How has ReWalk Robotics performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: 2RW is currently unprofitable.
Growing Profit Margin: 2RW is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: 2RW is unprofitable, but has reduced losses over the past 5 years at a rate of 6.9% per year.
Accelerating Growth: Unable to compare 2RW's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: 2RW is unprofitable, making it difficult to compare its past year earnings growth to the Medical Equipment industry (8.2%).
Return on Equity
High ROE: 2RW has a negative Return on Equity (-144.26%), as it is currently unprofitable.
How is ReWalk Robotics's financial position?
Financial Position Analysis
Short Term Liabilities: 2RW's short term assets ($21.1M) exceed its short term liabilities ($10.2M).
Long Term Liabilities: 2RW's short term assets ($21.1M) exceed its long term liabilities ($3.4M).
Debt to Equity History and Analysis
Debt Level: 2RW's debt to equity ratio (64.6%) is considered high.
Reducing Debt: Insufficient data to determine if 2RW's debt to equity ratio has reduced over the past 5 years.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: 2RW has sufficient cash runway for more than a year based on its current free cash flow.
Forecast Cash Runway: 2RW has sufficient cash runway for 1.1 years if free cash flow continues to reduce at historical rates of 1% each year.
What is ReWalk Robotics's current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate 2RW's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate 2RW's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if 2RW's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if 2RW's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of 2RW's dividend in 3 years as they are not forecast to pay a notable one for the German market.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Larry Jasinski (62yo)
Mr. Lawrence J. Jasinski, also known as Larry, BS, MBA has been the Chief Executive Officer at ReWalk Robotics Ltd. (formerly Argo Medical Technologies) since February 12, 2012. From 2005 to 2012, Mr. Jasi ...
CEO Compensation Analysis
Compensation vs Market: Larry's total compensation ($USD553.51K) is about average for companies of similar size in the German market ($USD430.63K).
Compensation vs Earnings: Larry's compensation has been consistent with company performance over the past year.
|CEO & Director||8.25yrs||US$553.51k||0.033% $4.9k|
|Chief Financial Officer||2.25yrs||US$276.84k||0.0049% $722.2|
|Vice President of QA & Operations||3.25yrs||no data||no data|
|Vice President of Marketing & Reimbursement||2.17yrs||no data||no data|
|Vice President of Customer Service||2.17yrs||no data||no data|
|Executive Advisor to the CEO||2.58yrs||US$310.00k||no data|
Experienced Management: 2RW's management team is considered experienced (2.4 years average tenure).
|CEO & Director||8.25yrs||US$553.51k||0.033% $4.9k|
|Independent Director||11.33yrs||US$25.00k||0.045% $6.6k|
|Independent Director||5.67yrs||US$73.95k||0.045% $6.6k|
|Independent Chairman of the Board||11.33yrs||US$25.00k||0.017% $2.5k|
|Independent Director||2yrs||US$70.31k||0.044% $6.6k|
|Independent Director||7.33yrs||US$25.00k||0.045% $6.6k|
|Independent Director||6.33yrs||US$25.00k||0.045% $6.6k|
Experienced Board: 2RW's board of directors are considered experienced (7.3 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have been substantially diluted in the past year, with total shares outstanding growing by 186.3%.
ReWalk Robotics Ltd.'s company bio, employee growth, exchange listings and data sources
- Name: ReWalk Robotics Ltd.
- Ticker: 2RW
- Exchange: DB
- Founded: 2001
- Industry: Health Care Equipment
- Sector: Healthcare
- Market Cap: US$16.296m
- Listing Market Cap: US$14.739m
- Shares outstanding: 12.93m
- Website: https://www.rewalk.com
Number of Employees
- ReWalk Robotics Ltd.
- 3 Hatnufa Street
- 6th Floor
- Yokneam Illit
|Ticker||Exchange||Primary Security||Security Type||Country||Currency||Listed on|
|RWLK||NasdaqCM (Nasdaq Capital Market)||Yes||Ordinary Shares||US||USD||Sep 2014|
|2RW||DB (Deutsche Boerse AG)||Yes||Ordinary Shares||DE||EUR||Sep 2014|
ReWalk Robotics Ltd., a medical device company, designs, develops, and commercializes robotic exoskeletons for individuals with mobility impairments or other medical conditions. It offers ReWalk Personal for everyday use to paraplegic individuals at home and in their communities; and ReWalk Rehabilitation for exercise and therapy used in hospitals and rehabilitation centers in the United States and Europe. The company is also developing ReWalk Restore, a soft suit exoskeleton for rehabilitation of individuals suffering from a stroke. It markets and sells its products directly to third party payers, institutions and individuals, as well as through third-party distributors. The company was formerly known as Argo Medical Technologies Ltd. ReWalk Robotics Ltd. was founded in 2001 and is headquartered in Yokneam Ilit, Israel.
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2020/05/28 23:49|
|End of Day Share Price||2020/05/28 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.